Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19

Inclusion Criteria:

1. Women and men over 18 years old

2. Clinical diagnosis of COVID19 infection (to be subsequently confirmed by PCR or
specific IgM isotype Ac and with entry criteria according to the protocol of action
(see Annex 2)

3. Acceptance and signing of the consent for the study after having received the
appropriate information.

Exclusion criteria

1. Known allergy or hypersensitivity to any of the medications included in the treatment
arms or to any of their components.

2. Contraindication for the use of any of the medications included (*)

- CsA: IR EST 4.5 (FG <30 ml / min according to the Cockcroft-Gault formula)

- Antimalarials (Chloroquine, hydroxychloroquine): Retinopathy, Myasthenia gravis.

- Lopinavir / ritonavir: severe liver failure

- Remdesivir, darunovir-ritonavir

- Doxycycline, Azithromycin

3. Kidney failure (Stages 4 and 5: GFR <30 ml / min according to the cockcroft-Gault
formula).

4. Decompensated liver disease (Child-Pugh stages B or C) or chronic infection with virus
B

5. Pregnancy or lactation

6. Age over 75 years

7. Participants in another clinical trial with medication in the 28 days prior to the
start of recruitment. Participation in observational studies is allowed.

8. Refusal to participate

9. Patient with a poor state of health or nutrition who, in the opinion of the
researcher, has sufficient criteria of severity to interfere with the development of
the study or its conclusions

10. At the investigator's discretion, the patient's inability to understand or comply with
the study procedures